Answers are grounded in this paper and cite their sources.
As the number of therapeutic options expands, the management of inflammatory bowel disease (IBD) increases in complexity. In such an environment, it is important to occasionally survey current practices against the goals of treatment to ensure that patients’ needs are being met and outcomes optimized. Five experts in the field of inflammatory bowel disease discussed these issues at a special roundtable held in October 2002 in Seattle, Washington. MODERATOR (DR. LICHTENSTEIN): I would like to begin with the first question, “What are the goals of medical therapy for Crohn’s disease?” DR. PRESENT: I believe the primary goals are to first induce a remission and then maintain a remission. We’ve been studying this for a long time, and we’ve been trying to find drugs that will do both, hopefully both at the same time. For example, to try and induce a remission with a 5-ASA [5-aminosalicylic acid] agent and then keep the patient better (maintenance of remission) with a 5-ASA agent.
No takes yet. Share an insight, caveat, or question.
Lichtenstein et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: